Larvol Veri

BIOMARKER:

KRAS G12C

Entrez ID:

3845

Related biomarkers:

‹

›

KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib Sensitive: B - Late Trials sotorasib Sensitive : B
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
KRAS G12C KRAS G12C	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12C KRAS G12C	Colorectal Cancer CRC	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	MRTX849 Sensitive: C2 – Inclusion Criteria MRTX849 Sensitive : C2
KRAS G12C KRAS G12C	Colorectal Cancer CRC	cetuximab + MRTX849 Sensitive: C2 – Inclusion Criteria cetuximab + MRTX849 Sensitive : C2
KRAS G12C KRAS G12C	Colorectal Cancer CRC	sotorasib Sensitive: C2 – Inclusion Criteria sotorasib Sensitive : C2
KRAS G12C KRAS G12C	Solid Tumor Solid Tumor	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C KRAS G12C	Lung Cancer Lung Cancer	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C KRAS G12C	Colorectal Cancer CRC	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	SAR442720 Sensitive: C2 – Inclusion Criteria SAR442720 Sensitive : C2
KRAS G12C KRAS G12C	Ampulla of Vater Carcinoma Ampulla of Vater Carcinoma	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12C KRAS G12C	Pancreatic Cancer Pancreatic Cancer	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3
KRAS G12C KRAS G12C	Cholangiocarcinoma Cholangiocarcinoma	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C KRAS G12C	Ovarian Cancer Ovarian Cancer	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C KRAS G12C	Pancreatic Cancer Pancreatic Cancer	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C KRAS G12C	Endometrial Cancer Endometrial Cancer	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C KRAS G12C	Colorectal Cancer CRC	MRTX849 Sensitive: C3 – Early Trials MRTX849 Sensitive : C3
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KRAS G12C KRAS G12C	Solid Tumor Solid Tumor	MRTX1257 + IN10018 Sensitive: C3 – Early Trials MRTX1257 + IN10018 Sensitive : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES